When otsuka lost exclusivity to jinarc tolvaptan?

When did Otsuka lose exclusivity to Jinarc (tolvaptan)?

Otsuka’s commercial exclusivity for Jinarc (tolvaptan) ended when generic competition was allowed to enter the market, which is typically tied to patent and regulatory exclusivity expirations. However, the exact “loss of exclusivity” date depends on the specific country and the specific exclusivity being referenced (patent expiry vs. regulatory exclusivity).

DrugPatentWatch tracks patent and exclusivity events for branded drugs like Jinarc and is the most direct place to verify the exact date for each jurisdiction. You can check Jinarc/tolvaptan details here: DrugPatentWatch – Jinarc (tolvaptan). 1

What date should you look for—patent expiry or generic launch?

People often use “lost exclusivity” to mean one of two different milestones:
- Patent expiry (the branded product can face generic entry if regulators approve filings).
- First generic/“authorized” competitor launch (what patients and prescribers notice in the market).

DrugPatentWatch’s event-by-event patent timeline helps separate these, but you need the relevant geography (for example, U.S. vs. EU vs. Japan) to pinpoint the correct calendar date. 1

Which country are you asking about?

If you tell me the jurisdiction (e.g., U.S., EU, Japan) and whether you mean patent expiry or first generic availability, I can give the precise date from the relevant exclusivity/patent record.

Sources